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Introduction: Pancreatic ductal adenocarcinoma (PDAC) commonly presents later in
life with a median age at diagnosis of 70 years. Unfortunately, elderly patients are
significantly underrepresented in clinical trials. Stereotactic body radiation therapy (SBRT)
is a promising treatment modality in this population as it has demonstrated excellent local
control with minimal toxicity. We aimed to determine prognostic factors associated with
outcomes in elderly patients treated with SBRT.
Materials and Methods: Elderly patients older than 70 treated with SBRT for PDAC at
our institution, from 2004 to 2014 were included. Our primary endpoints included overall
survival (OS) and local-progression-free survival (LPFS). Secondary endpoints included
regional-progression-free survival (RPFS), distant-progression-free-survival (DPFS) and
radiation toxicity. Endpoints were analyzed with the Kaplan-Meier method. The
association of these survival endpoints with risk factors was studied with Cox proportional
hazards models.
Results: We identified 145 patients with 146 lesions of pancreatic adenocarcinoma with
a median age at diagnosis of 79 (range, 70.1–90.3). SBRT was delivered to a median
dose of 36Gy (IQR 24–36). Surgical resection was performed on 33.8% of the total
patients. Median follow-up was 12.3 months (IQR 6.0–23.3 months) and the median
survival for the entire cohort 14.0 months with a 2-year OS of 27%. Multivariate analysis
(MVA) demonstrated surgery [p ≤ 0.0001, HR 0.29 (95% CI, 0.16–0.51)] and post-SBRT
CA19-9 [p = 0.009, HR 1.0004 (95% CI, 1.0002–1.0005)] significantly associated
with overall survival. Recurrent lesions [p = 0.0069, HR 5.1 (95% CI, 1.56–16.64)]
and post-SBRT CA19-9 levels [p = 0.0107, HR 1.0005 (95% CI, 1.0001–1.0008)]
were significantly associated with local control on MVA. For the entire cohort, 4.1%
experienced acute grade 2+ toxicity, and 2% experienced late grade 2+ toxicity at 2
years.
Conclusion: This review demonstrates prognostic factors in elderly patients with PDAC
treated with SBRT. We identified surgical resection and post-SBRT CA 19-9 as predictive
of overall survival in this population. Additionally, we show low acute and late toxicity
following SBRT in elderly patients.
Keywords: pancreatic cancer, elderly population, stereotactic body radiation therapy, prognostic factors, radiation
toxicity
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INTRODUCTION
Pancreatic adenocarcinoma is the 11th most common cause
of new cancer cases, but is the third leading cause of
cancer mortality in the United States. Despite aggressive
multidisciplinary efforts in recent years, the 5-year mortality
remains dismal at 10–30% depending on the resectable status
(1–3). Currently, surgical resection remains the most significant
prognostic factor, with adjuvant chemotherapy playing and
important supportive role. Notably, elderly patients make up a
considerable proportion of those with pancreatic cancer with
a median age at diagnosis of 70 years and median age at
death of 72 years (4). Unfortunately, although elderly patients
account for half of this population, they are significantly
underrepresented in clinical trials meant to guide treatment
decisions (5). This underrepresentation makes it difficult to
extrapolate the role of various treatment strategies for this specific
population.
Elderly patients with pancreatic adenocarcinoma present a
myriad of challenges making it difficult to administer aggressive
multi-modality treatment. Standard treatment with invasive
surgical procedures and multi-agent chemotherapy may not
be tolerable in frail patients with significant comorbidities (6,
7). Additionally, traditional radiation therapy with 6 weeks of
external beam radiation therapy (EBRT) has been associated with
significant treatment-related morbidity (8). Stereotactic body
radiation therapy (SBRT) was developed to deliver a high dose
of radiation therapy in few treatments while minimizing dose to
surrounding tissue (9). This method has demonstrated excellent
local control with minimal toxicity in a variety of diseases (10,
11). Herein we aimed to determine outcomes in elderly patients
treated with SBRT for pancreatic adenocarcinoma.
METHODS
Patient Population
In accordance with our institutional review board, elderly
patients (age >70) with histologically-proven pancreatic
adenocarcinoma between 2004 and 2014 were reviewed. Patients
with resectable, borderline resectable, unresectable, medically-
inoperable, and recurrent tumors were included in this study.
Patients were excluded if they had distant metastasis at diagnosis.
SBRT was performed using either a CyberKnife R© robotic
radiosurgery (Accuray Inc., Sunnyvale, CA) or non-robotic
linear accelerator based platforms (Trilogy R© or TrueBeam R©)
(Varian Medical Systems, Palo Alto, CA). Patient variables
included were age, race, gender, surgical status, chemotherapy
treatment, prior EBRT, and SBRT dose, dosimetry, and toxicity
were collected.
Definition of Parameters
Resectable status was determined by a multidisciplinary
case review using National Comprehensive Cancer Network
(NCCN) guidelines for resectable, borderline resectable, and
unresectable disease. Prophylactic proton-pump inhibitors was
not routinely recommended for patients. Local, regional, and
distant progression were determined based on radiographic
findings on follow up and/or confirmatory biopsy if done. Local
progression was identified as progressive disease (PD) using
RECIST 1.1 criteria which is characterized by at least a 20%
increase in the sum of diameters of the tumor and a minimum
of a 5mm increase (12). Regional failure was defined as disease
progression to the regional nodes defined as n1, n2, or n3 by
the Japanese Pancreas Society (JPS) classification (13, 14) (or
new tumor growth within the pancreas outside of the radiation
field). Toxicity was graded retroactively with the Common
Terminology Criteria for Adverse Events Version 4.0 (CTCAE
4.0). Patients included in this review were simulated in the supine
position using four-dimensional CT-scan, utilizing 1.25mm
slices, with IV contrast in a vacuum lock bag and wingboard.
The GTV was determined based on the simulation CT scan and
diagnostic CT scans. The PTV margin was added to be ∼3mm
from GTV. When the GTV or PTV abutted the GI luminal
structures, we cropped the PTV out the bowel and accepted
underdosing of the GTV and PTV with no specific target volume
criteria at those areas. Patients included in the study had fiducials
placed before CT-simulation to assist with target delineation
during treatment. Patients were treated to either 36Gy in 3
fractions or 24Gy in one fraction. The bowel was our major
dose limiting structured and was limited to no more than 20Gy
(single fraction) and 30Gy (multi-fraction) maximum dose.
The max dose for the kidneys, liver, and cord were limited to
10Gy, 20Gy, 5Gy (single fraction), and 15Gy, 50Gy, and 15Gy
(multi-fraction) respectively. Notably one patient exceeded the
max dose for the left and right kidney (28.8Gy and 29.0Gy
respectively).
Endpoints
Our primary endpoints included overall survival (OS) from
diagnosis and local-progression-free survival (LPFS) from
SBRT. Secondary endpoints included regional-progression-free-
survival (RPFS), distant-progression-free-survival (DPFS), and
acute and late toxicity.
Statistical Analysis
Continuous variables were summarized with median and inter-
quartile range (IQR). Categorical variables were summarized
with frequency and percentage. The survival endpoints, LPFS,
OS, RPFS, and DPFS, were analyzed with the Kaplan-Meier
method. Patients were censored at last medical follow-up. The
association of these survival endpoints with risk factors was
studied with univariate Cox proportional hazards models. To
build multivariable Cox models for the survival endpoints, the
stepwise variable selection was performed. All the variables from
univariate models that had a p-value of < 0.1 were included
as potential predictors. Variables were subsequently removed
from the multivariable model if the p-value was > 0.05. All p-
values reported are two-sided. Acute toxicity was reported as
crude rates occurring within 3 months of treatment. Late toxicity
was considered toxicity that occurred >3 months following
treatment. Actuarial late toxicity estimates were calculated by the
Kaplan-Meier methods. The effect of factors on grade 2+ and
grade 3+ toxicities were analyzed with logistic regressionmodels.
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RESULTS
Patient Characteristics
A detailed list of patient characteristics can be found in Table 1.
We identified 145 patients with 146 lesions of pancreatic
adenocarcinoma with a median age at diagnosis of 79 (range
70.1–90.3) with 55% female and 45% male. Tumors were
most commonly located in the head (69%) of the pancreas.
Nine patients (6%) had prior radiation with a median dose
of 50.4Gy (IQR, 50.4–55.8) in a median of 14.9 months
prior to SBRT. Surgical stage at diagnosis, deemed in a
multidisciplinary case review, included, resectable (30.3%),
borderline resectable (15.9%), and unresectable (53.8%).
Surgical resection was performed on 33.8% of the total
patients. No patients with unresectable disease at diagnosis
received a resection. Chemotherapy was given prior to (42.1%),
concurrent with (4.1%) or follow SBRT (37.2%) Chemotherapy
regimens included gemcitabine alone (45%), gemcitabine
+ capecitabine (29%), gemcitabine + other additional
chemotherapy (20%), and FU based chemotherapy regimens
(7%). Prior to SBRT, CA19-9 was elevated in 63.7%% (n= 93) of
patients.
SBRT Treatment Characteristics
SBRT was delivered by either Trilogy R© (43%), Truebeam R©
(28%), or CyberKnife R© (28%) in either one (37%) or multiple
fractions (63%). Median BED10 and EQD2 were 81.6 (range
50.40–87.5) Gy and 68 (range 42–72.9) Gy (single fraction) and
79.2 (range 51.3–79.2) Gy and 66 (range 42.8–66) Gy (multi-
fraction) respectively. Patients received SBRT as either definitive
treatment (65.8%), or as neoadjuvant (8.3%) or adjuvant (25.5%)
therapy in resected patients.Median dose was 36Gy (IQR 24–36).
For the entire cohort median gross tumor volume (GTV) was 13
cm3 (IQR 8.7–25) and planning target volume (PTV) was 18 cm3
(IQR 12.6–32). Following SBRT, CA19-9 levels were remeasured
in a median of 1.9 months (IQR 1.2–2.9). Of the 93 patients with
elevated baseline CA19-9 levels, 6 patients returned to normal
levels following SBRT.
Overall Survival
Within a median follow-up of 12.3 months (IQR 6.0–23.3
months) the median survival from diagnosis for the entire cohort
14.0 months (95% CI: 12.3–16.5) with 1- and 2-year OS of 60%
and 27.0%, respectively (Table 2). Median OS by resectability
status was 24.4 months (95%CI: 15.6–33.1), 15.9 months (95%CI:
3.4–18.3), and 10.0 months (95%CI: 7.8–12.3) for resectable,
borderline resectable, and unresectable, respectively. Univariate
analysis demonstrated worse OS was significantly associated with
increased age [p < 0.0081, HR 1.04 (95% CI, 1.01–1.070)],
elevated pre-SBRT CA19-9 [p = 0.004, HR 1.00022 (95% CI,
1.00007–1.000360)], elevated post-SBRT CA19-9 [p < 0.001, HR
1.0004 (95% CI, 1.0002–1.00060)], increased stage [p < 0.001,
HR 1.90 (95% CI, 1.52–2.37)], and increased PTV [p = 0.044,
HR 1.01 (95% CI, 1.00–1.030)]. Improved OS was observed with
recurrent lesions [p = 0.0173, HR 0.51 (95% CI, 0.30–0.89)],
surgery [p < 0.001, HR 0.30 (95% CI, 0.20–0.45)], increased
SBRT dose [p = 0.040, HR 0.97 (95% CI, 0.94–1.00)], and
TABLE 1 | Patient and treatment characteristics.
Characteristics Value (n = 145 patients)
Age (years, range) 70.1–90.3
Gender
Female 80 (55%)
Male 65 (45%)
CA19-9 value (Median value, IQR)
At diagnosis 293.3 (101, 798)
Pre-SBRT 120.3 (34, 473.8)
Post-SBRT 85 (29.3, 436)
Change in CA19-9 −4.8 (−67.25, 79.95)
Surgical stage
Resectable 44 (30.3%)
Borderline resectable 23 (15.9%)
Unresectable 78 (53.8%)
Surgery
Yes 49 (33.8%)
No 96 (66.2%)
Location
Body 14 (10%)
Head 100 (69%)
Tail 2 (1%)
Uncinate 9 (6%)
Neck 7 (5%)
Genu 1 (1%)
Multiple 12 (8%)
Prior radiation (yes/no)
No 136 (94%)
Yes 9 (6%)
Previous EBRT Dose (Median, IQR) 50.4 (50.4, 55.8)
Treatment platform
Trilogy 63 (43%)
CyberKnife 41 (28%)
Truebeam 41 (28%)
Chemotherapy
Yes 103 (71.0%)
No 37 (24.8%)
Unavailable 9 (6.2%)
Chemotherapy timing
Before SBRT 61 (42.1%)
Concurrent 5 (3.4%)
After SBRT 54 (37%)
Chemotherapy agent
Gemcitibine 41 (45%)
Gemcitibine + Capcitabine 27 (29%)
Gemcitibine + other 18 (20%)
FU based 6 (7%)
GTV (cm3) (Median, IQR) 13 (8.7, 25)
PTV (cm3) (Median, IQR) 18 (12.6, 32)
Fractionation
Single 54 (37%)
Multi-fraction 91 (63%)
Dose (Median, IQR) 36 (24, 36)
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TABLE 2 | Kaplan-Meier estimates for OS, LPFS, RPFS, and DPFS.
Kaplan Meier-Estimates All cohort
Median follow-up
From diagnosis—months (IQR) 12.3 (6.0–23.3)
Median survival
Median survival—months (95% I) 40 (12.3–16.5)
12-months 60.0%
24-months 27.0 %
Local control from SBRT
Median time to LF (95%CI) Median not reached (20.8–infinity)
12-months 72%
24-months 63%
Regional control from SBRT
Median time to RF (95% CI) Median not reached (N/A)
12-months 92%
24-months 92%
Distant metastases free survival
Median time to DM (95% CI) 23.1 (14.4–33.6)
12-months 62%
24-months 47%
post-SBRT CA19-9 normalization [p = 0.045, HR 0.35 (95% CI,
0.12–0.980)]. On multivariate analysis, only surgery [p = 0.002,
HR 0.36 (95% CI, 0.19–0.70)], post-SBRT CA19-9 normalization
[p = 0.037, HR 0.32 (95%CI, 0.10–0.94)], and post-SBRT CA19-
9 [p = 0.003, HR 1.0004 (95% CI, 1.0001–1.0005)] maintained
significance on multivariate analysis (Table 3). Median survival
for patients receiving resection was 28.3 months (95% CI: 16.2–
40.5) vs. 11.4 months (95% CI: 9.3–13.5) in those without
resection.
Local Control
One- and 2-year LPFS is 72 and 63%, respectively for the entire
cohort (Figure 1). Univariate analysis demonstrated significantly
worse 2-year LPFS associated with elevated post-SBRT CA19-
9 [p = 0.0216, HR 1.0038 (95% CI, 1.00006–1.00071)], and
recurrent lesions [p < 0.005, HR 3.31 (95% CI, 1.42–7.68)].
Improved 2-year LPFS was observed with multi-fraction SBRT
[p = 0.0189, HR 0.45 (95% CI, 0.23–0.88)]. On multivariate
analysis, multi-fraction SBRT did not hold significance for
superior local control. Only recurrent lesions [p= 0.0069, HR 5.1
(95% CI, 1.56–16.64)], and post-SBRT CA19-9 levels [p= 0.0107,
HR 1.0005 (95% CI, 1.0001–1.0008)] maintained significance on
multivariate analysis (Table 4). Within this cohort, 6.9% (n= 10)
died of local progression.
Regional and Distant Progression Free
Survival
One- and 2-year RPFS rates were both 92%. None of the
variables analyzed were found to be significantly associated
with inferior regional control on univariate or multivariate
analysis (Table 6s supplementary). At 1 and 2 years, the
Kaplan-Meier estimated rate of DPFS was 62 and 47%,
TABLE 3 | Results of univariate and multivariate cox regression models for OS.
Factor Hazard ratio (95% confidence
interval)
p-value
Univariate
Age 1.04 (1.01, 1.07) 0.008
CA19-9 at diagnosis 1.00003 (0.99999, 1.00006) 0.145
Pre-SBRT CA19-9 1.00022 (1.00007, 1.00036) 0.004
Post-SBRT CA19-9 1.0004 (1.0002, 1.0006) <0.001
Change in CA19-9 1.00007 (0.99972, 1.00043) 0.687
CA19-9 normalization 0.35 (0.12, 0.98) 0.045
Previous EBRT Dose 0.03 (0.00, infinity) 0.998
Recurrent lesion vs.
non-recurrent
0.51 (0.30, 0.89) 0.017
GTV volume (cm3) 1.004 (0.995, 1.013) 0.390
PTV volume (cm3) 1.01 (1.00, 1.03) 0.044
BED ≥ 60 0.77 (0.45, 1.30) 0.3268
Multiple fractions vs. single
fraction
0.72 (0.51, 1.02) 0.068
Chemo: Gemcitibine +
Capcitabine vs. Gemcitibine
0.92 (0.54, 1.55) 0.746
Chemo: FU based vs.
Gemcitibine
0.51 (0.18, 1.44) 0.203
Stage 1.90 (1.52–2.37) <0.001
Surgery vs. no surgery 0.30 (0.20, 0.45) <0.001
Dose 0.97 (0.94, 1.00) 0.040
Multivariate analysis
Surgery 0.36 (0.19, 0.70) 0.002
CA19-9 Normalization 0.32 (0.1, 0.94) 0.037
Post-SBRT CA19-9 1.0004 (1.0001, 1.0005) 0.003
respectively. Univariate analysis identified elevated CA19-9
at diagnosis [p = 0.0006, HR 1.00015 (95% CI, 1.00006–
1.00023)], and elevated pre-SBRT CA 19-9 [p = 0.0016, HR
1.00034 (95% CI, 1.00031–1.00056)] associated with inferior
DPFS and surgery [p = 0.0493, HR 0.55 (95% CI, 0.31–1.00)]
associated with superior DPFS (Table 7s in Supplementary
Material). None of these variables maintained significance
on multivariate analysis. Treatment fractionation was not
found to be associated with either regional control or distant
metastases.
Radiation Toxicity
For the entire cohort, 4.1 and 0.7% of patients experienced
acute grade 2+ and 3+ toxicity respectively. Acute grade
2 toxicity included gastritis (n = 1), nausea (n = 2),
and maculopapular rash (n = 2). One patient experienced
acute grade 3 nausea requiring hospitalization. At 2-years
late grade 2+ and 3+ toxicity was 2 and 1% respectively.
One patient experienced a late grade 4 duodenal stenosis (8
months after SBRT) requiring urgent operative intervention.
This patient was treated in 3 fractions and received a
max dose to the small bowel of 25.5Gy. This was likely
a result of radiation and not tumor progression as there
were no signs of local or regional progression. Two patients
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FIGURE 1 | Kaplan Meier curves for OS and LPFS.
TABLE 4 | Results of univariate and multivariate Cox regression models for time to
local progression.
Factor Hazard ratio (95% confidence
interval)
p-value
Univariate
Age 1.001 (0.946, 1.060) 0.962
CA19-9 at diagnosis 0.99997 (0.99974, 1.00019) 0.769
Pre-SBRT CA19-9 0.9996 (0.9986, 1.0005) 0.359
Post-SBRT CA19-9 1.00038 (1.00006, 1.00071) 0.022
Change in CA19-9 1.0003 (0.9998, 1.0008) 0.196
CA19-9 normalization 1.01 (0.28, 3.61) 0.9912
Previous EBRT Dose 0.01 (0.00, infinity) 1.000
Recurrent lesion vs.
non-recurrent
3.31 (1.42, 7.68) 0.005
GTV volume 1.005 (0.988, 1.021) 0.570
PTV volume 1.01 (0.98, 1.03) 0.543
BED ≥ 60 2.09 (0.50, 8.73) 0.3136
Multiple fractions vs. single
fraction
0.45 (0.23, 0.88) 0.019
Chemo: Gemcitibine +
Capcitabine vs. Gemcitibine
0.51 (0.21, 1.24) 0.138
Chemo: FU based vs.
Gemcitibine
0.62 (0.14, 2.72) 0.528
Stage 0.87 (0.59, 1.28) 0.45
Surgery vs. no surgery 0.83 (0.41, 1.69) 0.615
Dose 0.94 (0.89, 1.00) 0.049
Multivariate
Recurrent lesion 5.10 (1.56, 16.64) 0.007
Post-SBRT CA19-9 1.0005 (1.0001, 1.0008) 0.011
experienced late grade 3 toxicity which included nausea
(n = 1) and enteritis (n = 1). None of the variables
analyzed with univariate logistic regression were found to be
significantly associated with acute or late grade 2+ or grade 3+
toxicity.
DISCUSSION
Pancreatic adenocarcinoma is primarily a malignancy of
the elderly; however, this geriatric population is frequently
underrepresented in clinic trials that aim to guide treatment
decisions (5). As these patients are frequently more medically
complex, special considerations need to be given when
determining treatment planning. The dearth of evidence however
makes this task especially challenging as the benefit of various
treatment options is unclear. This retrospective review aimed to
look for prognostic factors associated with outcomes for elderly
patients treated with SBRT for pancreatic adenocarcinoma.
Our results did not identify any differences in overall survival,
local, regional, or distant control, or toxicity between single
or multi-fraction regimens. In contrast, our previous work
looking at 289 patients (291 lesions) of all ages with pancreatic
adenocarcinoma identified multi-fraction SBRT associated with
improved local control on multivariate analysis [p = 0.009, HR
0.53 (95% CI, 0.33–0.85)] with a 2-year local control of 69.7 and
56.8% for multi-fraction and single fraction, respectively. It is
possible that our lack of statistical significance on multivariate
analysis is the smaller sampler size of the present study (n= 145)
compared to our much larger previous report on all ages
(n= 289).
Previously, Zhu et al. reported on outcomes of pancreatic
cancer patients aged over 65 years treated with SBRT. They
reported on 417 patients with advanced andmedically inoperable
pancreatic cancer with a median age of 73 years. Patients
were treated with 30-46.8Gy in 5–8 fractions. One-year OS,
progression free survival (PFS), local-recurrence free survival
(LRFS), and distant metastasis free survival (DMFS) were 35.5,
18.2, 26.6, and 27.1% respectively. Tumor stage, tumor response
at 6 months, and CA19-9 level normalization at 3 months
were all identified as predictors for OS, PFS, LRFS, and DMFS.
Additionally, patients receiving 5-FU demonstrated improved
survival compared to gemcitabine based chemotherapy. Finally,
patients with BED10 ≥ 60Gy achieved better tumor response as
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compared to those who received BED10 < 60Gy (15). Compared
to the present study, Zhu et al. reported worse outcomes for
1-year OS (35.5 vs. 60.0%), LRFS (26.6 vs. 72.0%), and DMFS
(27.1 vs. 62%). These differences were likely a result of our report
including patients with resectable disease. As such, 33.8% of
patients in our cohort received surgical resection compared to
12.8% leading to the disparity in outcomes. Regarding prognostic
factors, we also identified CA19-9 normalization to predict
overall survival but not local control, regional control, or freedom
from distant metastasis.
Unfortunately, as with, non-elderly patients, only 10–20%
of patients are deemed to have resectable disease at the time
of diagnosis (16–18). In addition to a large proportion of
elderly patients having unresectable disease, elderly patients fare
even worse as they are more likely to be medically-inoperable
due to significant comorbidities. This has generated interest in
radiation as definitive treatment for these patients. Specifically,
SBRT has been the modality of choice for definitive treatment
as its shorter duration allows patients to receive full dose
systemic therapy with less delay (19). Burton et al. reported
on 26 patients ≥ 80 years with pancreatic adenocarcinoma
treated with definitive SBRT (24 Gy/ 1 fraction or 30-36 Gy/
3 fractions) +/–chemotherapy. Median overall survival was 7.6
months with 34.6% 1-year survival and median local control
was 11.5 months with 41.2% 1-year local control. This cohort
exhibited no acute or late grade 3+ toxicity (20). The results
of our study compare favorably with improved survival and
local control however it is important to note our study included
surgical patients which accounted for 34% (n= 49) of our cohort.
Additionally, our cohort included younger patients than those
above.
Compared to historical controls, our outcomes with SBRT
appear to have a greater impact on resected patients than when
used as definitive treatment. Prior reports have demonstrated
a median OS of 16.1–23.4 months for resected patients treated
with adjuvant chemotherapy alone or chemoradiation with
EBRT (6, 7). Our results compare favorably with median OS
of 28.1 months for resected patients treated with SBRT and
chemotherapy. However, for patients with locally advanced
disease, receiving either chemotherapy alone or chemoradiation
with EBRT, median OS ranges from 8.6 to 11.4 months which
is similar to our reported 11.4 months for patients receiving
definitive SBRT (21–23).
The present study continues to support the prognostic role
of CA19-9. Overall survival has been associated with both
kinetic changes during chemotherapy as well as static values
post operatively (24, 25). Additionally, as we have shown in our
previous report of all ages, post-SBRT CA19-9 was associated
with inferior overall survival and local control on multivariate
analysis (26). Although numerous reports have demonstrated
the prognostic importance of CA19-9 in the entire population,
few studies have assessed if this holds true for elderly patients.
Frakes et al. assessed pancreatic cancer outcomes in the elderly
and found post-operative CA19-9 greater than 90 (p< 0.001, HR
2.81) was associated with worse survival (6).
The present study also identified recurrent pancreatic
adenocarcinoma significantly associated with inferior local
control. Treatment of recurrent pancreatic cancer has been
challenging due to limited therapeutic options (27, 28). Surgical
re-resection, EBRT, SBRT, and systemic chemotherapy have all
been used and have their limitations (29–32). The precision
SBRT provides is especially useful in recurrent patients as
they have often received prior radiation therapy. Previous
reports have identified SBRT to be a safe and reasonable
treatment option for locally recurrent pancreatic cancer capable
of providing symptoms palliation (33, 34). Within our cohort,
recurrent patients were often treated with reirradiation, and it
is therefore possible that their SBRT treatment plan was more
conservative to reduce potential toxicity. This could have led to
the observed inferior local control compared to non-recurrent
tumors. Additionally, it is possible that recurrent tumors are
more locally aggressive and therefore likely to re-recur.
Here we add to currently limited literature of pancreatic
cancer treatment in elderly patients. This identified no differences
in outcomes or toxicity between single fraction and multi-
fraction SBRT for this cohort. Further, we confirmed SBRT for
pancreatic adenocarcinoma in elderly patients to be a safe and
effective treatment modality for this challenging population with
very low rates of toxicity. This study however was limited by
its retrospective nature. Firstly, patients were treated on three
different treatment platforms and received a non-standardized
treatment regimen. The patients included in this study also
represented a heterogeneous population including resectable,
borderline resectable, and unresectable patients that received
various surgical and chemotherapeutic treatments. Additionally,
we did not have any object data regarding pain control or
symptom palliation following treatment which represents a
critically important aspect among elderly patients. Finally, our
toxicity may be underrepresented due to poor follow-up with
radiation oncology. Prospective studies will be needed for
a more rigorous assessment of the role of fractionation on
patient outcomes and the role of SBRT in the elderly more
generally.
CONCLUSION
Surgical resection, post-SBRT CA 19-9, and post-SBRT CA 19-
9 normalization appears to be predictive of clinical outcomes in
elderly patients with pancreatic adenocarcinomas. SBRT can be
delivered with minimal acute and late toxicity and therefore little
impact on patients’ quality of life. Future studies should further
refine treatments based on these characteristics.
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